Clinical Trials
18 trialsNCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01843725 2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1 Completed
NCT00036946 2016-06-03
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00045266 2016-06-03
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00082823 2016-06-03
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00083213 2016-06-03
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00644124 2016-05-06
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Sanofi
Phase 1 Completed
NCT00876044 2016-05-05
QUTIE
Sanofi
Phase 1 Completed
NCT01688960 2015-03-17
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT01930552 2015-01-07
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
Sanofi
Phase 1 Completed
NCT00650923 2014-05-30
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00622414 2014-02-24
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00545246 2013-10-16
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
Sanofi
Phase 1 Completed
NCT00921661 2012-11-09
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Sanofi
Phase 1 Completed
NCT01148615 2012-01-13
A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
Sanofi
Phase 1 Completed
NCT00479076 2011-01-26
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
Sanofi
Phase 1 Completed